Therefore, the study proposes a novel therapeutic strategy: IFN-γ combined with IDO1 or AhR inhibitor can disrupt the dormancy of TRCs and induce their apoptosis, thus achieving more effective tumor clearance 44. The gene discussed is IDO1; the disease is neoplasm.